GOSSAMER BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
GOSSAMER BIO, INC. (GOSS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $6.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-13
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $2.50M, a 38.89% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $4.10M, a 6.82% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $1.60M, a 51.52% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $1.80M, a 55.00% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month |
|---|---|---|---|
| 2026-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.60M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $4.10M 10-Q · filed 2026-05-15 | ||
| 2025-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.40M derived: sum of 2 quarters · filed 2026-08-13 | $7.80M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.20M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $4.40M 10-Q · filed 2026-05-15 | ||
| 2024-09-30 | $3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.30M derived: sum of 2 quarters · filed 2025-11-05 | $12.00M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $8.70M 10-Q · filed 2025-08-05 | |
| 2024-03-31 | $4.70M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |